Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK exec caught off-guard by China graft charges: sources

Thu, 15th May 2014 09:14

By Adam Jourdan and Kazunori Takada

SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be chargedwith leading a network of corruption in China's pharmaceuticalindustry, two sources with ties to the businessman and knowledgeof the investigation said.

The allegations against the Briton, who as GSK's China headwas the firm's legal representative in the country, are the mostserious charges ever laid against a foreign national forcorporate corruption in China, lawyers said.

Police said they had charged Reilly and two Chinesecolleagues with multiple offences on Wednesday, after a 10-monthprobe found the firm made billions of yuan from schemes to bribedoctors and hospitals.

"The fact that Mark's name was on the list of people chargedwas definitely a surprise," said a source with direct knowledgeof the investigation. The source declined to be named because ofthe sensitivity of the case.

Police findings are usually upheld in Chinese courts,meaning Reilly and the other executives could face decades injail.

GSK did not respond to requests for comment on Thursday.

Britain's biggest drugmaker said in a statement on Wednesdaythat the allegations were "deeply concerning" and it hoped to"reach a resolution" that would enable it to continue to operatein China, a key growth market for Western pharmaceutical giants.

Reilly, a scientist and accountant who has been with GSK forover two decades, briefly left China after the scandal broke inJuly last year. He voluntarily returned to assist authoritieswith the probe, with insiders saying the understanding was thiswould shield him from charges.

"I've had regular contact with Mark over the past fewmonths. I would think that this state of affairs is a surpriseto him. I don't think he is prepared, or thought that he couldbe culpable," an industry executive in China who has personalties to Reilly said.

Attempts to reach Reilly were unsuccessful.

NEXT STEPS

The last major corruption scandal to hit a foreign companyin China involved miner Rio Tinto in 2009,which resulted in four executives including a Chinese-bornAustralian being jailed for between seven and 14 years.

Reilly and two Chinese executives, Zhang Guowei and ZhaoHongyan, are charged with corporate bribery, bribingnon-government officials and bribing business units.

Officials gave no specific details on the amount of bribespaid or how much the company had illegally earned, althoughpreviously they accused the firm of funnelling up to 3 billionyuan ($482 million) to travel agencies to facilitate bribes todoctors and officials.

According to normal process, Reilly should have beendetained as soon as authorities laid charges against him.

Police could not be reached for comment and the Britishconsulate declined to comment on Reilly's whereabouts. Theindustry executive said he believed the Briton was still inShanghai.

Reilly had likely been barred from leaving China after hisreturn to help with the investigation, lawyers said.

WAKE-UP CALL

The prosecution will now examine the case before passing itto the courts, which could take as little as a month or muchlonger if further investigation is required, lawyers said.

GSK is the most prominent of a number of graft probes thathave been launched against global drug firms since last year,and authorities are unlikely to risk the investigation beingoverturned in the courts.

"For a sensitive and closely followed case like this, thepolice and prosecutors will have consulted with each otheralready," said Leon Liu, Shanghai-based partner at law firm MWEChina.

Chinese officials visited other international drugmakersincluding Novartis AG, AstraZeneca Plc, SanofiSA, Eli Lilly & C o and Bayer AG last year as part of a broad investigation into the sector,which is rife with bribery between sales staff and doctors.

Legal experts said the GSK case was a wake-up call toforeign companies that thought their top expatriate executiveswere immune from criminal charges as authorities step up acrackdown on corruption ordered by President Xi Jinping.

"There's a notion that only people of Chinese nationalityare going to go to jail here," said Steven Dickinson,Qingdao-based partner with law firm Harris Moure.

"People always say they'll never put a Briton or an Americanin jail. But they will, and this is just that example." (Additional reporting by John Ruwitch in SHANGHAI; Editing byStephen Coates)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.